ClinicalTrials.gov
public full text
Public Domain
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
The primary objective is to test the following hypothesis: Patients with metastatic castrate resistant prostate cancer that have progressed following at least one line of therapy and have an immunogenic signature will respond to combined PD-1 and CTLA4 inhibition.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer#898078
- pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer#152482
- Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)#261521
- Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy#314352
- Nivolumab in Biochemically Recurrent dMMR Prostate Cancer#835407
Record · ID 1101995
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive